ATE490975T1 - 4-methylhexanoic kahalalide f verbindung - Google Patents

4-methylhexanoic kahalalide f verbindung

Info

Publication number
ATE490975T1
ATE490975T1 AT03779140T AT03779140T ATE490975T1 AT E490975 T1 ATE490975 T1 AT E490975T1 AT 03779140 T AT03779140 T AT 03779140T AT 03779140 T AT03779140 T AT 03779140T AT E490975 T1 ATE490975 T1 AT E490975T1
Authority
AT
Austria
Prior art keywords
kahalalide
methylhexanoic
compound
antitumoral
antiviral
Prior art date
Application number
AT03779140T
Other languages
English (en)
Inventor
Glynn Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Aviles
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/en
Application granted granted Critical
Publication of ATE490975T1 publication Critical patent/ATE490975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03779140T 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f verbindung ATE490975T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (1)

Publication Number Publication Date
ATE490975T1 true ATE490975T1 (de) 2010-12-15

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03779140T ATE490975T1 (de) 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f verbindung

Country Status (13)

Country Link
KR (2) KR20110114690A (de)
AT (1) ATE490975T1 (de)
AU (1) AU2003285911B2 (de)
CA (1) CA2501089C (de)
CY (1) CY1111319T1 (de)
DE (1) DE60335292D1 (de)
DK (1) DK1572726T3 (de)
ES (1) ES2357644T3 (de)
IL (1) IL167724A (de)
NO (1) NO333448B1 (de)
PL (1) PL209129B1 (de)
PT (1) PT1572726E (de)
SI (1) SI1572726T1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US7473681B2 (en) * 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
EP1435990A1 (de) * 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalid-verbindungen zur verwendung in der krebstherapie

Also Published As

Publication number Publication date
KR20050070056A (ko) 2005-07-05
KR20110114690A (ko) 2011-10-19
CA2501089A1 (en) 2004-04-29
CA2501089C (en) 2012-07-17
KR101149095B1 (ko) 2012-05-30
PT1572726E (pt) 2011-02-14
SI1572726T1 (sl) 2011-04-29
PL209129B1 (pl) 2011-07-29
CY1111319T1 (el) 2015-08-05
DE60335292D1 (de) 2011-01-20
HK1082261A1 (en) 2006-06-02
NO333448B1 (no) 2013-06-10
AU2003285911A1 (en) 2004-05-04
AU2003285911B2 (en) 2009-11-19
DK1572726T3 (da) 2011-03-28
NO20052379L (no) 2005-07-15
IL167724A (en) 2012-01-31
ES2357644T3 (es) 2011-04-28
PL377056A1 (pl) 2006-01-23
NO20052379D0 (no) 2005-05-13

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
EA200401157A1 (ru) N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
BG66080B1 (bg) Заместени тиоацетамиди
NO20082298L (no) Kaliumkanalinhibitorer
ATE486915T1 (de) Azeotrop-ähnliche zusammensetzung von 1,2-dichlor-3,3,3-trifluorpropen und fluorwasserstoff
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
SE9901077D0 (sv) Novel use
ATE431343T1 (de) Thio-analoga von paclitaxel und deren vorprodukte
WO2004035613A3 (en) 4-methylhexanoic kahalaide f compound
MXPA02011039A (es) Combinaciones de productos activos fungicidas.
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
DE60335292D1 (de) 4-methylhexanoic kahalalide f verbindung
EA200200948A1 (ru) Лечение псориаза
BR0312183A (pt) Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica
FR2825896B1 (fr) Poudre acaricide
EA200100853A1 (ru) Резорциновая композиция
PT1259502E (pt) Analogos biologicamente activos da discodermolida
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572726

Country of ref document: EP